Document is current
Any future updates will be listed below
-
Authors
Pu, Ting
Peddle, Allyson M.
Wirapati, Pratyaksha
Tsantoulis, Petros
Wu, Qian
Hong, Yourae
Samuel, Leslie
Desai, Jayesh
Riener, Maigo
Saridaki, Zacharenia
Cunningham, David
Tejpar, Sabine
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1SF0424N)
Chinese Scholarship Council (202206380034)
- License Information
-
More Information
Article History
Received: 7 October 2025
Accepted: 14 December 2025
First Online: 13 January 2026
Competing interests
: J. Desai reports consulting or advisory roles for Amgen (institutional), Axelia Oncology, Bayer, BeiGene, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH, Ellipses Pharma, GlaxoSmithKline, Incyte, Merck KGaA, Novartis, Pfizer, Pierre Fabre, and Roche/Genentech. He also reports research funding from Amgen (institutional), AstraZeneca/MedImmune (institutional), BeiGene (institutional), Bristol-Myers Squibb (institutional), GlaxoSmithKline (institutional), Novartis (institutional), and Roche (institutional). D. Cunningham reports stock and other ownership interests in OVIBIO, as well as consulting or advisory roles for OVIBIO. He has received research funding from 4SC (institutional), Bayer (institutional), Clovis Oncology (institutional), Leap Oncology (institutional), Lilly (institutional), MedImmune (institutional), and Roche (institutional). S. Tejpar reports honoraria from Merck Serono and Regeneron; consulting or advisory roles for Bayer, Boehringer Ingelheim, Merck Serono, Regeneron, and Roche/Genentech; speakers’ bureau participation for Bristol-Myers Squibb, Merck Serono, MSD, Roche, and Sanofi; and travel, accommodations, and expenses from Amgen, Bayer, Merck Serono, Roche, and Sanofi. The remaining authors have declared no conflicts of interest.
: All participants provided written informed consent prior to enrolment.
